Once we confirmed the significant expression of these ICs in two out of three cell lines, we tested the effects of the human monoclonal antibodies, currently in clinical use for cancer treatment, [35] Nivolumab and Ipilimumab (anti-PD-1 and anti-CTLA-4 respectively) and of other human anti-PD-L1 (10_12 and PD-L1_1), anti-PD-1 (PD-1_1) or anti-CTLA-4 (ID1) immunomodulatory mAbs, previously generated in our laboratory by a novel selection strategy on activated human peripheral blood mononuclear cells (hPBMCs) [6,27,28,36]. This evidence concerns the gene CD274 and cancer.